The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial

INTRODUCTION: While adjuvant immunotherapy with Bacille Calmette Guérin (BCG) is effective in non-muscle-invasive bladder cancer (BC), adverse events (AEs) are considerable. Monocyte-derived activated killer cells (MAK) are discussed as essential in antitumoural immunoresponse, but their application...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, Maximilian, Thiounn, Nicolas, Denzinger, Stefan, Kondas, Jozsef, Benoit, Gerard, Chapado, Manuel S, Jimenz-Cruz, Fernando J, Kisbenedek, Laszlo, Szabo, Zoltán, Zsolt, Domján, Grimm, Marc O, Romics, Imre, Thüroff, Joachim W, Kiss, Tamas, Tombal, Bertrand, Wirth, Manfred, Munsell, Marc, Mills, Bonnie, Koh, Tung, Sherman, Jeff
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893125/
https://www.ncbi.nlm.nih.gov/pubmed/20529333
http://dx.doi.org/10.1186/1479-5876-8-54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893125/
https://www.ncbi.nlm.nih.gov/pubmed/20529333
http://dx.doi.org/10.1186/1479-5876-8-54

Ejemplares similares